Author:
Jones Trace M.,Carew Jennifer S.,Nawrocki Steffan T.
Abstract
Kidney cancer is the 7th most prevalent form of cancer in the United States with the vast majority of cases being classified as renal cell carcinoma (RCC). Multiple targeted therapies have been developed to treat RCC, but efficacy and resistance remain a challenge. In recent years, the modulation of autophagy has been shown to augment the cytotoxicity of approved RCC therapeutics and overcome drug resistance. Inhibition of autophagy blocks a key nutrient recycling process that cancer cells utilize for cell survival following periods of stress including chemotherapeutic treatment. Classic autophagy inhibitors such as chloroquine and hydroxychloroquine have been introduced into phase I/II clinical trials, while more experimental compounds are moving forward in preclinical development. Here we examine the current state and future directions of targeting autophagy to improve the efficacy of RCC therapeutics.
Funder
National Cancer Institute
Reference88 articles.
1. Cancer statistics, 2019
2. Treatment of renal cell carcinoma: Current status and future directions
3. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
4. Cancer Statistics Review;Noone,2018
5. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer; Version 2.2020
https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献